Veeva Systems demonstrates a powerful combination of accelerating revenue growth, reaching 17.6% in 2027Q2, and significant operating margin expansion to 29.6%, driven by strong operating leverage in its core subscription business.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 17.6% in 2027Q2, while operating margin has expanded to 29.6%, demonstrating powerful operating leverage as operating income grew 77% year-over-year.
Veeva delivers a comprehensive industry cloud for life sciences, combining software, AI, data, and consulting services, serving over 1,500 customers.
Veeva's AI Agents for Vault CRM and PromoMats enhance productivity across clinical, regulatory, safety, quality, medical, and commercial operations.
The company benefits from high-margin recurring revenue streams, strong cash flows, and a robust $5 billion net cash position.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 26, 2026 | $2.35+5.4% vs $2.23 | $928M+2.5% vs $905M |
Q3 2026 Jun 3, 2026 | $2.24+4.7% vs $2.14 | $883M+2.9% vs $858M |
Q2 2026 Mar 4, 2026 | $2.06+6.2% vs $1.94 | $836M+3.1% vs $811M |
Q4 2025 Nov 20, 2025 | $2.04+4.6% vs $1.95 | $811M+2.3% vs $793M |
Veeva Systems NYSE: VEEV said it remains on track to reach a $6 billion revenue run rate by calendar 2030, as the life sciences software provider expands its artificial intelligence offerings and pursues more business from clinical research organizations.
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Veeva Systems (VEEV). But which of these two companies is the best option for those looking for undervalued stocks?
Agentic CRM platform to drive unified engagement worldwide PLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB has committed to Veeva Vault CRM, the agentic engagement platform for life sciences.
Veeva System earns a Buy rating, justified by re-accelerating revenue growth, rare 45% operating margins, and sticky regulated software. VEEV trades at a 70% P/E premium to the sector but below its five-year average, with a PEG of 0.97x versus the sector median of 1.87x. Recent strategic wins include 14 of the top 20 biopharma CRM commitments and IQVIA standardizing on Veeva's clinical applications.
Benchmark VEEV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Veeva Systems Inc. (VEEV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $303.73 | $49.34B | 55.83 | 16.34% | 28.44% | 13.93% | — | |
| $213.65 | $174.98B | 27.39 | 9.58% | 21.99% | 20.15% | 0.78% | |
| $32.51 | $6.08B | 33.17 | 13.05% | 25.48% | 16.95% | — | |
| $653.11 | $18.23B | 42.74 | 19.97% | 18.24% | 99.76% | — | |
| $200.61 | $10.27B | 233.27 | 19.17% | 4.26% | 7.75% | — | |
| $93.99 | $8.08B | 49.21 | 14.44% | 24.25% | 11.73% | — |
Veeva Systems Inc. (VEEV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Veeva Systems Inc. (VEEV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
Aug 20, 2026·SEC
Apr 20, 2026·SEC
Get notified when VEEV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Veeva Systems Inc. (VEEV) stock FAQ — growth, dividends, profitability & financials explained
Veeva Systems Inc. (VEEV) reported $3.46B in revenue over the trailing twelve months. Revenue was $3.20B in fiscal year 2026. That is 5116% more than the $61.3M of fiscal year 2012.
Veeva Systems Inc. (VEEV) grew revenue by 16.3% in fiscal year 2026, compared with the prior fiscal year.
Yes. Veeva Systems Inc. (VEEV) earned $1.01B in net income over the trailing twelve months (a 29.3% net margin).
Veeva Systems Inc. (VEEV) had a return on equity (ROE) of 13.9% in fiscal year 2026. That is in line with the market's typical 10-15%.
Veeva Systems Inc. (VEEV) generated $517.0M in free cash flow over the trailing twelve months.
